Biotechnology Stocks List

This page shows information about the 50 largest biotechnology industry stocks including LianBio, PHAXIAM Therapeutics, Kaleido Biosciences, and PolarityTE.

1. LianBio NASDAQ:LIAN

$0.19 0.00 (-1.68%)

As of 02/14/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Market Capitalization: $20.89 million
P/E Ratio: -0.24
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 154 shares
Average Volume: 1.04 million shares
Today's Range: $0.19
▼
$0.19
50-Day Range: $0.19
▼
$0.29
52-Week Range: $0.27
▼
$4.99
Dividend Yield: N/A

2. PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 02/14/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Market Capitalization: $10.58 million
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: N/A
Average Volume: 2,472 shares
Today's Range: $3.10
▼
$3.10
50-Day Range: $3.10
▼
$3.10
52-Week Range: $2.50
▼
$13.00
Dividend Yield: N/A

3. Kaleido Biosciences NASDAQ:KLDO

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Market Capitalization: $6.39 million
P/E Ratio: 0.00
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: N/A
Average Volume: 3,204 shares
Today's Range: $0.00
▼
$0.00
50-Day Range: $0.00
▼
$0.00
52-Week Range: $0.00
▼
$0.25
Dividend Yield: N/A

4. PolarityTE NASDAQ:PTEIQ

$0.15 0.00 (0.00%)

As of 02/14/2025

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Market Capitalization: $1.09 million
P/E Ratio: -0.05
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 19 shares
Average Volume: 27,292 shares
Today's Range: $0.15
▼
$0.15
50-Day Range: $0.11
▼
$0.20
52-Week Range: $0.05
▼
$0.09
Dividend Yield: N/A

5. 9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Market Capitalization: $1.04 million
P/E Ratio: -0.02
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: N/A
Average Volume: 315,915 shares
Today's Range: $0.00
▼
$0.00
50-Day Range: $0.00
▼
$0.00
52-Week Range: $0.07
▼
$6.56
Dividend Yield: N/A

6. Rocket Pharmaceuticals NASDAQ:RCKTW

$0.08 0.00 (-5.54%)

As of 02/14/2025 03:57 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 29,530 shares
Average Volume: 38,118 shares
Today's Range: $0.07
▼
$0.09
50-Day Range: $0.02
▼
$0.09
52-Week Range: $0.02
▼
$0.40
Dividend Yield: N/A

7. NeuroSense Therapeutics NASDAQ:NRSNW

$0.23 -0.06 (-20.60%)

As of 02/14/2025 02:16 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 1,157 shares
Average Volume: 2,530 shares
Today's Range: $0.23
▼
$0.30
50-Day Range: $0.15
▼
$0.53
52-Week Range: $0.10
▼
$1.06
Dividend Yield: N/A

8. Revelation Biosciences NASDAQ:REVBW

$0.02 0.00 (-10.16%)

As of 02/14/2025 03:15 PM Eastern

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 56,284 shares
Average Volume: 120,149 shares
Today's Range: $0.0151
▼
$0.0185
50-Day Range: $0.0066
▼
$0.0188
52-Week Range: $0.00
▼
$0.04
Dividend Yield: N/A

9. NRx Pharmaceuticals NASDAQ:NRXPW

$0.13 -0.03 (-18.59%)

As of 02/14/2025 03:57 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 24,890 shares
Average Volume: 42,593 shares
Today's Range: $0.07
▼
$0.18
50-Day Range: $0.06
▼
$0.40
52-Week Range: $0.04
▼
$0.50
Dividend Yield: N/A

10. Revolution Medicines NASDAQ:RVMDW

$0.10 -0.06 (-36.67%)

As of 02/14/2025 03:51 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 83,012 shares
Average Volume: 20,884 shares
Today's Range: $0.09
▼
$0.12
50-Day Range: $0.10
▼
$0.34
52-Week Range: $0.05
▼
$0.80
Dividend Yield: N/A

11. Nutriband NASDAQ:NTRBW

$1.78 0.00 (0.00%)

As of 02/14/2025

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 115 shares
Average Volume: 18,656 shares
Today's Range: $1.78
▼
$1.78
50-Day Range: $1.17
▼
$4.03
52-Week Range: $0.19
▼
$5.25
Dividend Yield: N/A

12. Reviva Pharmaceuticals NASDAQ:RVPHW

$0.13 -0.02 (-12.84%)

As of 02/14/2025 03:54 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 40,446 shares
Average Volume: 31,338 shares
Today's Range: $0.13
▼
$0.15
50-Day Range: $0.11
▼
$0.50
52-Week Range: $0.07
▼
$1.11
Dividend Yield: N/A

13. OmniAb NASDAQ:OABIW

$0.44 +0.00 (+0.68%)

As of 02/14/2025 04:00 PM Eastern

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 2,118 shares
Average Volume: 2,626 shares
Today's Range: $0.42
▼
$0.46
50-Day Range: $0.28
▼
$0.45
52-Week Range: $0.24
▼
$1.39
Dividend Yield: N/A

14. SAB Biotherapeutics NASDAQ:SABSW

$0.04 +0.01 (+19.54%)

Closing price 02/14/2025 03:57 PM Eastern

Extended Trading

$0.04 +0.00 (+3.05%)

As of 02/14/2025 04:01 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 2,498 shares
Average Volume: 51,386 shares
Today's Range: $0.04
▼
$0.04
50-Day Range: $0.03
▼
$0.14
52-Week Range: $0.01
▼
$0.19
Dividend Yield: N/A

15. Ocean Biomedical NASDAQ:OCEAW

$0.02 0.00 (-10.66%)

As of 02/14/2025 03:59 PM Eastern

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 39,207 shares
Average Volume: 120,130 shares
Today's Range: $0.03
▼
$0.03
50-Day Range: $0.02
▼
$0.04
52-Week Range: $0.02
▼
$0.70
Dividend Yield: N/A

16. Surrozen NASDAQ:SRZNW

$0.03 +0.00 (+13.83%)

As of 02/14/2025 03:40 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 14,223 shares
Average Volume: 15,390 shares
Today's Range: $0.02
▼
$0.03
50-Day Range: $0.02
▼
$0.06
52-Week Range: $0.01
▼
$0.11
Dividend Yield: N/A

17. Oculis NASDAQ:OCSAW

$10.16 +0.18 (+1.80%)

As of 02/14/2025 04:00 PM Eastern

Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 5,045 shares
Average Volume: 32,216 shares
Today's Range: $10.00
▼
$10.20
50-Day Range: $4.73
▼
$11.29
52-Week Range: $1.60
▼
$11.50
Dividend Yield: N/A

18. 60 Degrees Pharmaceuticals NASDAQ:SXTPW

$0.03 0.00 (0.00%)

As of 02/14/2025

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: N/A
Average Volume: 29,760 shares
Today's Range: $0.03
▼
$0.03
50-Day Range: $0.02
▼
$0.04
52-Week Range: $0.01
▼
$0.15
Dividend Yield: N/A

19. Lixte Biotechnology NASDAQ:LIXTW

$0.05 +0.01 (+25.63%)

Closing price 02/14/2025 03:52 PM Eastern

Extended Trading

$0.05 0.00 (-5.20%)

As of 02/14/2025 04:12 PM Eastern

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 9,844 shares
Average Volume: 4,639 shares
Today's Range: $0.03
▼
$0.05
50-Day Range: $0.02
▼
$0.05
52-Week Range: $0.02
▼
$0.11
Dividend Yield: N/A

20. TC Biopharm NASDAQ:TCBPW

$0.02 0.00 (-8.99%)

As of 02/14/2025 03:57 PM Eastern

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 77,006 shares
Average Volume: 46,057 shares
Today's Range: $0.0113
▼
$0.0190
50-Day Range: $0.0087
▼
$0.0199
52-Week Range: $0.00
▼
$0.05
Dividend Yield: N/A

21. Moolec Science NASDAQ:MLECW

$0.04 +0.01 (+58.85%)

Closing price 02/14/2025 03:56 PM Eastern

Extended Trading

$0.05 +0.01 (+39.28%)

As of 02/14/2025 05:09 PM Eastern

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 21,589 shares
Average Volume: 8,011 shares
Today's Range: $0.02
▼
$0.04
50-Day Range: $0.02
▼
$0.06
52-Week Range: $0.02
▼
$0.17
Dividend Yield: N/A

22. Tevogen Bio NASDAQ:TVGNW

$0.08 +0.00 (+0.13%)

As of 02/14/2025 03:45 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 23,119 shares
Average Volume: 163,794 shares
Today's Range: $0.07
▼
$0.08
50-Day Range: $0.04
▼
$0.09
52-Week Range: $0.01
▼
$0.28
Dividend Yield: N/A

23. NewAmsterdam Pharma NASDAQ:NAMSW

$8.20 0.00 (0.00%)

As of 02/14/2025 01:21 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 50 shares
Average Volume: 2,354 shares
Today's Range: $8.20
▼
$8.20
50-Day Range: $8.12
▼
$15.99
52-Week Range: $5.52
▼
$16.75
Dividend Yield: N/A

24. Anew Medical NASDAQ:WENAW

$0.04 0.00 (-0.25%)

As of 09/16/2024

Anew Medical, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. Anew Medical, Inc. is based in Omaha, Nebraska.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 4,000 shares
Average Volume: 71,782 shares
Today's Range: $0.03
▼
$0.04
50-Day Range: $0.04
▼
$0.04
52-Week Range: $0.02
▼
$0.15
Dividend Yield: N/A

25. NKGen Biotech NASDAQ:NKGNW

$0.05 0.00 (-5.26%)

As of 02/14/2025 01:33 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 18,453 shares
Average Volume: 17,975 shares
Today's Range: $0.05
▼
$0.05
50-Day Range: $0.03
▼
$0.13
52-Week Range: $0.02
▼
$0.29
Dividend Yield: N/A

26. XOMA NASDAQ:XOMAO

$25.40 +0.05 (+0.18%)

As of 02/14/2025 03:57 PM Eastern

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 1,237 shares
Average Volume: 1,757 shares
Today's Range: $25.41
▼
$25.46
50-Day Range: $25.08
▼
$25.73
52-Week Range: $24.42
▼
$25.87
Dividend Yield: 9.00%

27. NLS Pharmaceutics NASDAQ:NLSPW

$0.02 +0.01 (+49.61%)

As of 02/14/2025 03:51 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 2,785 shares
Average Volume: 83,530 shares
Today's Range: $0.0125
▼
$0.0190
50-Day Range: $0.0051
▼
$0.0195
52-Week Range: $0.01
▼
$0.10
Dividend Yield: N/A

28. XOMA NASDAQ:XOMAP

$25.69 -0.29 (-1.11%)

Closing price 02/14/2025 03:54 PM Eastern

Extended Trading

$25.59 -0.10 (-0.39%)

As of 02/14/2025 04:01 PM Eastern

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 457 shares
Average Volume: 1,461 shares
Today's Range: $25.95
▼
$25.95
50-Day Range: $25.30
▼
$25.97
52-Week Range: $24.61
▼
$26.51
Dividend Yield: 9.29%

29. Protagenic Therapeutics NASDAQ:PTIXW

$0.0040 0.00 (0.00%)

As of 02/14/2025

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: N/A
Average Volume: 18,366 shares
Today's Range: $0.0040
▼
$0.0040
50-Day Range: $0.0040
▼
$0.0140
52-Week Range: $0.00
▼
$0.04
Dividend Yield: N/A

30. YS Biopharma NASDAQ:YSBPW

$0.06 -0.01 (-18.16%)

As of 02/14/2025

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 1,020 shares
Average Volume: 37,227 shares
Today's Range: $0.06
▼
$0.06
50-Day Range: $0.04
▼
$0.09
52-Week Range: $0.01
▼
$0.10
Dividend Yield: N/A

31. Pasithea Therapeutics NASDAQ:KTTAW

$0.03 0.00 (-7.55%)

Closing price 02/14/2025 03:05 PM Eastern

Extended Trading

$0.03 0.00 (-1.17%)

As of 02/14/2025 04:11 PM Eastern

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 11,213 shares
Average Volume: 23,714 shares
Today's Range: $0.02
▼
$0.03
50-Day Range: $0.02
▼
$0.04
52-Week Range: $0.01
▼
$0.10
Dividend Yield: N/A

32. ZIVO Bioscience NASDAQ:ZIVOW

$1.68 -0.19 (-10.16%)

As of 02/14/2025 10:24 AM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 100 shares
Average Volume: 8,337 shares
Today's Range: $1.68
▼
$1.68
50-Day Range: $1.17
▼
$2.00
52-Week Range: $0.12
▼
$2.38
Dividend Yield: N/A

33. Lexaria Bioscience NASDAQ:LEXXW

$0.34 +0.07 (+26.39%)

As of 02/14/2025 12:24 PM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 31,785 shares
Average Volume: 12,276 shares
Today's Range: $0.19
▼
$0.39
50-Day Range: $0.22
▼
$0.81
52-Week Range: $0.19
▼
$2.50
Dividend Yield: N/A

34. Apollomics NASDAQ:APLMW

$0.01 +0.00 (+9.09%)

As of 02/14/2025 03:54 PM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 9,996 shares
Average Volume: 25,886 shares
Today's Range: $0.0119
▼
$0.0120
50-Day Range: $0.0081
▼
$0.0149
52-Week Range: $0.01
▼
$0.04
Dividend Yield: N/A

35. 180 Life Sciences NASDAQ:ATNFW

$0.01 +0.00 (+6.54%)

As of 02/14/2025 03:49 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 49,186 shares
Average Volume: 170,776 shares
Today's Range: $0.01
▼
$0.0118
50-Day Range: $0.0075
▼
$0.0180
52-Week Range: $0.00
▼
$0.04
Dividend Yield: N/A

36. BriaCell Therapeutics NASDAQ:BCTXW

$0.12 0.00 (0.00%)

As of 02/14/2025 02:56 PM Eastern

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 140,666 shares
Average Volume: 110,495 shares
Today's Range: $0.10
▼
$0.13
50-Day Range: $0.11
▼
$0.54
52-Week Range: $0.08
▼
$1.89
Dividend Yield: N/A

37. Cardio Diagnostics NASDAQ:CDIOW

$0.07 0.00 (-4.72%)

As of 02/14/2025 03:04 PM Eastern

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 8,653 shares
Average Volume: 28,363 shares
Today's Range: $0.07
▼
$0.09
50-Day Range: $0.06
▼
$0.12
52-Week Range: $0.02
▼
$0.18
Dividend Yield: N/A

38. Conduit Pharmaceuticals NASDAQ:CDTTW

$0.01 0.00 (0.00%)

As of 02/14/2025

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: N/A
Average Volume: 211,473 shares
Today's Range: $0.0138
▼
$0.0138
50-Day Range: $0.0059
▼
$0.0179
52-Week Range: $0.01
▼
$0.15
Dividend Yield: N/A

39. Celularity NASDAQ:CELUW

$0.06 +0.00 (+0.16%)

As of 02/14/2025 03:57 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 35,850 shares
Average Volume: 33,688 shares
Today's Range: $0.06
▼
$0.08
50-Day Range: $0.02
▼
$0.08
52-Week Range: $0.01
▼
$0.11
Dividend Yield: N/A

40. CERo Therapeutics NASDAQ:CEROW

$0.02 +0.00 (+15.44%)

As of 02/14/2025 03:41 PM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 217,709 shares
Average Volume: 153,010 shares
Today's Range: $0.0147
▼
$0.0180
50-Day Range: $0.0074
▼
$0.0197
52-Week Range: $0.00
▼
$0.25
Dividend Yield: N/A

41. Cingulate NASDAQ:CINGW

$0.05 +0.01 (+22.54%)

As of 02/14/2025 03:23 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 64,435 shares
Average Volume: 30,734 shares
Today's Range: $0.04
▼
$0.05
50-Day Range: $0.03
▼
$0.10
52-Week Range: $0.01
▼
$0.18
Dividend Yield: N/A

42. Clene NASDAQ:CLNNW

$0.04 0.00 (0.00%)

As of 02/14/2025

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: N/A
Average Volume: 17,886 shares
Today's Range: $0.04
▼
$0.04
50-Day Range: $0.03
▼
$0.05
52-Week Range: $0.02
▼
$0.08
Dividend Yield: N/A

43. Comera Life Sciences NASDAQ:CMRAW

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: N/A
Average Volume: 43,247 shares
Today's Range: $0.00
▼
$0.00
50-Day Range: $0.0001
▼
$0.0008
52-Week Range: $0.0001
▼
$0.0001
Dividend Yield: N/A

44. Coeptis Therapeutics NASDAQ:COEPW

$0.02 0.00 (-12.00%)

As of 02/14/2025 03:40 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 43,475 shares
Average Volume: 122,869 shares
Today's Range: $0.02
▼
$0.03
50-Day Range: $0.01
▼
$0.04
52-Week Range: $0.01
▼
$0.06
Dividend Yield: N/A

45. Carmell NASDAQ:CTCXW

$0.04 +0.01 (+59.39%)

As of 02/14/2025 03:52 PM Eastern

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 4,385 shares
Average Volume: 19,330 shares
Today's Range: $0.03
▼
$0.04
50-Day Range: $0.02
▼
$0.08
52-Week Range: $0.02
▼
$0.50
Dividend Yield: N/A

46. Dermata Therapeutics NASDAQ:DRMAW

$0.03 +0.00 (+3.47%)

As of 02/14/2025 03:58 PM Eastern

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 7,018 shares
Average Volume: 17,109 shares
Today's Range: $0.03
▼
$0.03
50-Day Range: $0.01
▼
$0.03
52-Week Range: $0.01
▼
$0.03
Dividend Yield: N/A

47. Alpha Tau Medical NASDAQ:DRTSW

$0.36 +0.06 (+20.33%)

As of 02/14/2025 03:59 PM Eastern

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 74,167 shares
Average Volume: 41,982 shares
Today's Range: $0.30
▼
$0.38
50-Day Range: $0.19
▼
$0.43
52-Week Range: $0.09
▼
$0.50
Dividend Yield: N/A

48. eFFECTOR Therapeutics NASDAQ:EFTRW

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: N/A
Average Volume: 38,718 shares
Today's Range: $0.00
▼
$0.00
50-Day Range: $0.0006
▼
$0.0037
52-Week Range: $0.00
▼
$0.19
Dividend Yield: N/A

49. enGene NASDAQ:ENGNW

$0.97 +0.01 (+1.06%)

As of 02/14/2025 11:38 AM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: 481 shares
Average Volume: 5,553 shares
Today's Range: $0.78
▼
$1.05
50-Day Range: $0.75
▼
$1.27
52-Week Range: $0.42
▼
$6.50
Dividend Yield: N/A

50. Estrella Immunopharma NASDAQ:ESLAW

$0.08 0.00 (0.00%)

As of 02/14/2025

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Market Capitalization: N/A
P/E Ratio: N/A
Consensus Rating: N/A
Consensus Price Target: N/A
Volume: N/A
Average Volume: 2,140 shares
Today's Range: $0.08
▼
$0.08
50-Day Range: $0.05
▼
$0.09
52-Week Range: $0.03
▼
$0.19
Dividend Yield: N/A

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biotechnology Stocks List

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools